Hiscox S - Search Results

1

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI. Hiscox S, et al. Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21. Breast Cancer Res Treat. 2009. PMID: 18493848

2

Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA).

Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC. Jiang WG, et al. Among authors: hiscox s. Cancer Res. 1995 Nov 1;55(21):5043-8. Cancer Res. 1995. PMID: 7585549

3

Regulation of motility and invasion of cancer cells by human monocytic cells.

Jiang WG, Hiscox S, Hallett MB, Mansel RE, Puntis MC. Jiang WG, et al. Among authors: hiscox s. Anticancer Res. 1995 Jul-Aug;15(4):1303-10. Anticancer Res. 1995. PMID: 7654013

4

Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid.

Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF, Puntis MC. Jiang WG, et al. Among authors: hiscox s. Br J Cancer. 1995 Apr;71(4):744-52. doi: 10.1038/bjc.1995.145. Br J Cancer. 1995. PMID: 7710939 Free PMC article.

5

Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells.

Parr C, Hiscox S, Nakamura T, Matsumoto K, Jiang WG. Parr C, et al. Among authors: hiscox s. Int J Cancer. 2000 Feb 15;85(4):563-70. Int J Cancer. 2000. PMID: 10699931

6

Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.

Hiscox S, Parr C, Nakamura T, Matsumoto K, Mansel RE, Jiang WG. Hiscox S, et al. Breast Cancer Res Treat. 2000 Feb;59(3):245-54. doi: 10.1023/a:1006348317841. Breast Cancer Res Treat. 2000. PMID: 10832594

7

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490

8

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Hiscox S, et al. Clin Exp Metastasis. 2004;21(3):201-12. doi: 10.1023/b:clin.0000037697.76011.1d. Clin Exp Metastasis. 2004. PMID: 15387370

9

Zinc transporter LIV-1: a link between cellular development and cancer progression.

Taylor KM, Hiscox S, Nicholson RI. Taylor KM, et al. Among authors: hiscox s. Trends Endocrinol Metab. 2004 Dec;15(10):461-3. doi: 10.1016/j.tem.2004.10.003. Trends Endocrinol Metab. 2004. PMID: 15541644

10

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Jones HE, et al. Among authors: hiscox s. Endocr Relat Cancer. 2004 Dec;11(4):793-814. doi: 10.1677/erc.1.00799. Endocr Relat Cancer. 2004. PMID: 15613453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters